Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Palonosetron.

M Asif A Siddiqui1, Lesley J Scott

  • 1Adis International Limited, Mairangi Bay, Auckland, New Zealand. demail@adis.co.nz

Drugs
|May 14, 2004
PubMed
Summary
This summary is machine-generated.

Palonosetron effectively prevents chemotherapy-induced nausea and vomiting, showing superior or comparable results to other antiemetics in clinical trials. This serotonin 5-HT3 receptor antagonist is well-tolerated by cancer patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer.

Targeted oncology·2022
Same author

Correction to: Siponimod: A Review in Secondary Progressive Multiple Sclerosis.

CNS drugs·2021
Same author

Opicapone: A Review in Parkinson's Disease.

CNS drugs·2021
Same author

Lumasiran: First Approval.

Drugs·2021
Same author

Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer.

Targeted oncology·2020
Same author

Siponimod: A Review in Secondary Progressive Multiple Sclerosis.

CNS drugs·2020
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Pharmacology
  • Oncology
  • Clinical Trials

Background:

  • Chemotherapy-induced nausea and vomiting (CINV) is a significant challenge for cancer patients.
  • Serotonin 5-HT3 receptor antagonists are a key class of antiemetics.
  • Palonosetron is a novel, selective 5-HT3 receptor antagonist.

Purpose of the Study:

  • To evaluate the efficacy and safety of intravenous palonosetron for preventing CINV.
  • To compare palonosetron with ondansetron and dolasetron in cancer patients undergoing chemotherapy.

Main Methods:

  • Two randomized, double-blind trials involving 1132 patients receiving moderately emetogenic chemotherapy.
  • A separate trial with 667 patients receiving highly emetogenic chemotherapy.
  • Assessment of complete response rates (no emesis, no rescue medication) during acute (0-24h) and delayed (24-120h) phases.

Related Experiment Videos

Main Results:

  • Intravenous palonosetron (0.25 mg) was more effective than ondansetron (32 mg) for CINV prevention in both acute and delayed phases.
  • Palonosetron demonstrated comparable or superior efficacy to dolasetron.
  • Palonosetron (0.25 or 0.75 mg) showed efficacy similar to ondansetron in highly emetogenic chemotherapy settings.
  • Palonosetron was well-tolerated with minimal treatment-related adverse events and no significant effects on QT interval or lab parameters.

Conclusions:

  • Intravenous palonosetron is an effective and well-tolerated option for preventing CINV in patients receiving both moderately and highly emetogenic chemotherapy.
  • Palonosetron offers advantages over existing 5-HT3 antagonists, particularly in delayed CINV prevention.